We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00303407
First Posted: March 16, 2006
Last Update Posted: March 16, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Geneva
  Purpose
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Condition Intervention Phase
Cancer Venous Thromboembolism Drug: nadroparin Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by University Hospital, Geneva:

Study Start Date: January 2001
Estimated Study Completion Date: July 2002
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Cancer patients in palliative care
  • Patients fully informed about their condition
  • Signed informed consent
  • No exclusion criteria

Exclusion Criteria:

  • Absence of advanced cancer
  • Cancer previously cured
  • Venous thromboembolism diagnosed within 6 months prior to inclusion
  • Absence of discerning capacity
  • Active anti-thrombotic treatment with heparins or coumarines
  • Thrombocytopenia <50G/l
  • PTT >45sec
  • TP<35%
  • Active bleeding
  • Renal failure <20ml/min
  • Past history of heparin-induced thrombocytopenia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303407


Locations
Switzerland
Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Geneva, Switzerland, 1245
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Principal Investigator: Catherine Weber, MD Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00303407     History of Changes
Other Study ID Numbers: SPOT 99/54
First Submitted: March 15, 2006
First Posted: March 16, 2006
Last Update Posted: March 16, 2006
Last Verified: December 2005

Additional relevant MeSH terms:
Thromboembolism
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Nadroparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action